En analyse af bexarotens plasmakoncentration hos CTCL- patienter antydede, at samtidig indtagelse af gemfibrozil medførte en væsentlig forhøjelse af bexarotens plasmakoncentration.
A population analysis of plasma bexarotene concentrations in patients with CTCL indicated that concomitant administration of gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene.